No abstract available.
Adult ; Angiomyolipoma/pathology/*radiography/radionuclide imaging ; Carcinoma, Hepatocellular/pathology/radiography/radionuclide imaging ; Female ; Humans ; Immunohistochemistry ; Liver Function Tests ; Liver Neoplasms/pathology/radiography/radionuclide imaging ; Magnetic Resonance Imaging ; Positron-Emission Tomography ; Tomography, X-Ray Computed

OBJECTIVE: Angiomyolipoma is the most common benign kidney tumor. However, literature describing FDG PET findings on renal angiomyolipoma (AML) is limited. This study reports the FDG PET and PET/CT findings of 21 cases of renal AML. MATERIALS AND METHODS: The study reviews FDG PET and PET/CT images of 21 patients diagnosed with renal AML. The diagnosis is based on the classical appearance of an AML on CT scan with active surveillance for 6 months. The study is focused on the observation of clinical and radiographic features. RESULTS: Six men and 15 women were included in our study. The mean age of the patients was 57.14 +/- 9.67 years old. The mean diameter of 21 renal AML on CT scans was 1.76 +/- 1.00 cm (Min: 0.6 cm; Max: 4.4 cm). CT scans illustrated renal masses typical of AMLs, and the corresponding FDG PET scans showed minimal FDG activities in the area of the tumors. None of the 21 AMLs showed a maximum standardized uptake value (SUVmax) greater than 1.98. No statistically significant correlation was present between SUVmax and tumor size. CONCLUSION: Renal AMLs demonstrate very low to low uptake on FDG PET and PET/CT imaging in this study. When a fat-containing tumor in the kidney is found on a CT scan, it is critical to differentiate an AML from a malignant tumor including an RCC, liposarcoma, and Wilms tumor. This study suggests that FDG PET or PET/CT imaging is useful for differentiating a renal AML from a fat-containing malignant tumor.
Angiomyolipoma/*radionuclide imaging ; Contrast Media/diagnostic use ; Ehlers-Danlos Syndrome ; Female ; Fluorodeoxyglucose F18/diagnostic use ; Humans ; Kidney Neoplasms/*radionuclide imaging ; Male ; Middle Aged ; *Positron-Emission Tomography ; *Positron-Emission Tomography and Computed Tomography ; Radiopharmaceuticals/diagnostic use ; Retrospective Studies